Cervical cancer is a malignant neoplasm affecting the cervix. WHO reports that 500,000 women hear this diagnosis annually; about 300,000 females die because of cervical cancer every year. This oncological disease type has become one of the most ordinary reasons for females' deaths globally. However, the statistics can be much improved if the adequate treatment starts on time.

So, when a woman obtains such a diagnosis, it is essential to boost the treatment beginning. The disease stage significantly affects the outcome of cervical cancer treatment. For instance, the 5-year survival rate for the initial stage reaches up to 92%; for advanced stages, it hardly achieves 17%. The cancer disease stage influences the further tactics and the expenses needed to cover cervical cancer treatment. The initial stages are successfully treated by surgical intervention; for stages III, IV, doctors additionally administer chemo- and/or radiation therapies increasing the total cost of cervical malignant neoplasm treatment by several times.

Often, patients are afraid of wasting valuable time by waiting for the treatment covered by health insurance in their native countries. Sometimes low-income women can even refuse treatment because of high prices if they do not have health insurance at all. Luckily, it is possible to head abroad for receiving cost-effective therapy without queues for much lower prices.